The first ultrasound system for the ablation of prostate tissue in the United States has just been approved by the Food and Drug Administration (FDA). The Sonablate 450, developed by SonaCare Medical, is a minimally invasive treatment approach that uses high-intensity focused ultrasound (HIFU) to ablate prostate tissue. This is the same device that was previously not recommended for approval for use in prostate cancer.